Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

669P - CBX-12-101: Final results of a phase I study of CBX-12, a peptide drug conjugate (PDC) in patients (pts) with metastatic solid tumors

Date

14 Sep 2024

Session

Poster session 01

Topics

Tumour Site

Ovarian Cancer;  Breast Cancer

Presenters

Patricia Lorusso

Citation

Annals of Oncology (2024) 35 (suppl_2): S482-S535. 10.1016/annonc/annonc1589

Authors

P.M. Lorusso1, F. Meric-Bernstam2, N. Hafez3, I.I. Rodriguez Rivera4, D. Tripathy5, S. Wilks6, P. Pearson7, M.N. Needle8, A.W. Tolcher9

Author affiliations

  • 1 Medical Oncology Department, Yale School of Medicine - Radiology and Biomedical Imaging, 06520 - New Haven/US
  • 2 Investigational Cancer Therapeutics Department, The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US
  • 3 Medical Oncology, Yale University School of Medicine - Yale Cancer Center, 06520 - New Haven/US
  • 4 Oncology, NEXT OncologyTM, 78229 - San Antonio/US
  • 5 Breast Medical Oncology Dept., The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US
  • 6 Investigational Cancer Therapeutics Department, NEXT OncologyTM, 78229 - San Antonio/US
  • 7 Pharmacology, Monopteros Therapeutics, Inc., 01966 - Rockport/US
  • 8 Executive Department, Cybrexa Therapeutics, 06511 - New Haven/US
  • 9 Clinical Research Director, NEXT OncologyTM, 78229 - San Antonio/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 669P

Background

Tumor-targeted drug delivery technologies are urgently needed to overcome conventional chemotherapy’s lack of tumor selectivity. Alphalex conjugates, which contain a pH-low insertion peptide (pHLIP), a linker and a payload are designed to overcome this lack of selectivity. Alphalex PDCs target tumors in an antigen-independent manner. At pH 7.4, the peptide is unstructured. In the low pH tumor microenvironment the peptide forms an alpha helix and inserts directionally into the tumor cell membrane delivering the linker and payload. For CBX-12 the payload is exatecan.

Methods

In this Phase 1 trial, cohorts of pts were treated with escalating doses of CBX-12 in a 3 + 3 design. The primary objectives are safety, tolerability and to determine the MTD/RP2D. Secondary and exploratory objectives include evaluation of plasma PK of CBX-12 and exatecan, anti-tumor activity per RECIST v1.1, and measurement of anti-drug antibodies.

Results

Enrollment is complete with 69 pts having been treated on study. The most frequent treatment-related AEs (TRAEs) were anaemia (53.6%), leukopenia (42.0%), neutropenia (40.6%), nausea (39.1%), and fatigue (36.2%). The most frequent Gr3/4 TRAEs were neutropenia, (27.5%), anaemia (24.6%), leukopenia (21.7%), and thrombocytopenia (13.0%). No ILD or ophthalmic toxicity was reported. There were 5 confirmed responses in ovarian (2), breast (2), and colorectal cancer (1). Evidence of activity was also seen in NSCLC, cholangiocarcinoma, and thymic cancer. Of 12 patients with ovarian cancer there was one confirmed complete response, one confirmed partial response (PR) and tw0 unconfirmed PRs. 8 of 12 saw clinical benefit. The RP2D was established as 125mg/m2 every 21 days.

Conclusions

Tumor targeting facilitated by this pH sensitive peptide made possible an improved safety profile despite the administration of a 5-fold increase in the dose of exatecan compared to unconjugated exatecan. The dose limiting toxicity is myelosuppression. CBX-12 demonstrated broad activity with 5 confirmed responses in three malignancies. A randomized Phase 2 study in platinum resistant ovarian cancer is underway comparing two doses on the once every 21 day schedule.

Clinical trial identification

NCT04902872.

Editorial acknowledgement

Legal entity responsible for the study

Cybrexa Inc.

Funding

Cybrexa Inc.

Disclosure

F. Meric-Bernstam: Financial Interests, Personal and Institutional, Funding: Cybrexa, Inc. P. Pearson: Financial Interests, Personal, Financially compensated role, Consultant: Cybrexa, Inc. M.N. Needle: Financial Interests, Personal, Full or part-time Employment: Cybrexa, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.